Follow this preprint
Safety and immunogenicity of a heterologous booster with an RBD virus-like particle vaccine following two- or three-dose inactivated COVID-19 vaccine
Xiaolan Yong, Jun Liu, Ying Zeng, Jing Nie, Xuelian Cui, Tao Wang, Yilin Wang, Yiyong Chen, Wei Kang, Zhonghua Yang, Yan Liu
doi: https://doi.org/10.1101/2023.07.17.23292762
Now published in Human Vaccines & Immunotherapeutics doi: 10.1080/21645515.2023.2267869
Xiaolan Yong
ePhase I Clinical Trial Center, Chengdu Xinhua Hospital Affiliated to North Sichuan Medical College, Chengdu, Sichuan 610055, China;
Jun Liu
fPulmonary and Critical Care Medicine, Chongqing Red Cross Hospital (People’s Hospital of Jiangbei District), Chongqing 400020, China;
Ying Zeng
bGuangzhou Patronus Biotech Co. Ltd., Guangzhou, Guangdong 510320, China
cYantai Patronus Biotech Co. Ltd., Yantai, Shandong 265719, China;
Jing Nie
fPulmonary and Critical Care Medicine, Chongqing Red Cross Hospital (People’s Hospital of Jiangbei District), Chongqing 400020, China;
Xuelian Cui
dChongqing Medleader Bio-Pharm Co., Ltd., Chongqing 401338, China;
Tao Wang
dChongqing Medleader Bio-Pharm Co., Ltd., Chongqing 401338, China;
Yilin Wang
dChongqing Medleader Bio-Pharm Co., Ltd., Chongqing 401338, China;
Yiyong Chen
dChongqing Medleader Bio-Pharm Co., Ltd., Chongqing 401338, China;
Wei Kang
bGuangzhou Patronus Biotech Co. Ltd., Guangzhou, Guangdong 510320, China
cYantai Patronus Biotech Co. Ltd., Yantai, Shandong 265719, China;
Zhonghua Yang
bGuangzhou Patronus Biotech Co. Ltd., Guangzhou, Guangdong 510320, China
cYantai Patronus Biotech Co. Ltd., Yantai, Shandong 265719, China;
Yan Liu
aCollege of Pharmacy, Chongqing Medical University, Chongqing 400016, China
dChongqing Medleader Bio-Pharm Co., Ltd., Chongqing 401338, China;

Data Availability
The data used in the current study are available from the corresponding authors upon reasonable request.
Posted July 18, 2023.
Safety and immunogenicity of a heterologous booster with an RBD virus-like particle vaccine following two- or three-dose inactivated COVID-19 vaccine
Xiaolan Yong, Jun Liu, Ying Zeng, Jing Nie, Xuelian Cui, Tao Wang, Yilin Wang, Yiyong Chen, Wei Kang, Zhonghua Yang, Yan Liu
medRxiv 2023.07.17.23292762; doi: https://doi.org/10.1101/2023.07.17.23292762
Now published in Human Vaccines & Immunotherapeutics doi: 10.1080/21645515.2023.2267869
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
0
Author Videos
Subject Areas
- Addiction Medicine (423)
- Allergy and Immunology (746)
- Anesthesia (219)
- Cardiovascular Medicine (3234)
- Dermatology (270)
- Emergency Medicine (476)
- Epidemiology (13250)
- Forensic Medicine (19)
- Gastroenterology (891)
- Genetic and Genomic Medicine (5066)
- Geriatric Medicine (471)
- Health Economics (773)
- Health Informatics (3189)
- Health Policy (1129)
- Hematology (423)
- HIV/AIDS (1005)
- Medical Education (468)
- Medical Ethics (125)
- Nephrology (513)
- Neurology (4811)
- Nursing (254)
- Nutrition (716)
- Oncology (2483)
- Ophthalmology (702)
- Orthopedics (279)
- Otolaryngology (337)
- Pain Medicine (320)
- Palliative Medicine (89)
- Pathology (531)
- Pediatrics (1281)
- Primary Care Research (550)
- Public and Global Health (7372)
- Radiology and Imaging (1669)
- Respiratory Medicine (970)
- Rheumatology (473)
- Sports Medicine (415)
- Surgery (534)
- Toxicology (69)
- Transplantation (232)
- Urology (199)